INHIBACE PLUS

This brand name is authorized in Austria, Canada, Poland, South Africa, Spain, Turkey.

Active ingredients

The drug INHIBACE PLUS contains a combination of these active pharmaceutical ingredients (APIs):

1	Cilazapril UNII 19KW7PI29F - CILAZAPRIL
	Cilazapril is a specific, long-acting angiotensin-converting enzyme (ACE) inhibitor which suppresses the renin-angiotensin-aldosterone system and thereby the conversion of the inactive angiotensin I to angiotensin II, which is a potent vasoconstrictor.
	Read more about Cilazapril
2	Hydrochlorothiazide UNII 0J48LPH2TH - HYDROCHLOROTHIAZIDE
	Hydrochlorothiazide is a diuretic with antihypertensive properties. It acts by inhibiting the renal tubular re-absorption of sodium and chloride ions, which are excreted with an accompanying volume of water. Potassium excretion is also promoted.
	Read more about Hydrochlorothiazide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09BA08	Cilazapril and diuretics	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09B ACE inhibitors, combinations → C09BA ACE inhibitors and diuretics
Discover more medicines within C09BA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02181479
ES	Centro de información online de medicamentos de la AEMPS	60649
PL	Rejestru Produktów Leczniczych	100096008
TR	İlaç ve Tıbbi Cihaz Kurumu	8699511099034
ZA	Health Products Regulatory Authority	29/7.1.3/0022